bioAffinity Technologies, Inc. announced on November 4, 2024, the appointment of William Bauta, Ph.D., as its new Chief Science Officer. Dr. Bauta previously served as the company's Senior Vice President of Research and Development since 2016.
In his prior role, Dr. Bauta was responsible for multiple company inventions and patents, including improvements that optimized CyPath® Lung's performance and reduced costs. His expertise is expected to accelerate the commercial rollout of CyPath® Lung and expand the development pipeline.
Dr. Bauta succeeds Vivienne I. Rebel, M.D., Ph.D., who retired on October 31, 2024. This leadership transition maintains scientific rigor and business acumen at the helm of the company's product development efforts, focusing on advancing new technologies for early-stage disease detection.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.